A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE

Authors

  • Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya -

Keywords:

Finerenone, Chronic kidney disease, Solubility, BCS Class.

Abstract

Finerenone is a Novel selective Non-steroidal Mineralocorticoids  Receptor Antagonist. Finerenone is  indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.

Downloads

Published

-

How to Cite

Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya. (2023). A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE. EPRA International Journal of Research and Development (IJRD), 8(2), 200–202. Retrieved from http://www.eprajournals.net/index.php/IJRD/article/view/1554

Issue

Vol. 8 No. 2 (2023): EPRA International Journal of Research and Development (IJRD)

Section

Articles